Recombinant rotavirus expression system and recombinant rotaviruses
Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).
1. A recombinant rotavirus comprising a gene segment including a nucleotide sequence encoding an intact, full-length rotavirus nonstructural protein 3 (NSP3) and a nucleotide sequence encoding a non-rotavirus polypeptide, wherein the NSP3 and the non-rotavirus polypeptide are encoded by a single open reading frame, separated by a self-cleavage protease domain.
2. The recombinant rotavirus of claim 1 , wherein the self-cleavage protease domain is a 2A cleavage element.
3. The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is derived from a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus.
4. The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a second virus that is not rotavirus.
5. The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus.
6. The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is selected from the group consisting of norovirus VP1 protein, norovirus P domain, and norovirus P2 domain.
7. The recombinant rotavirus of claim 1 , wherein the recombinant rotavirus is based upon serotype G1P [8].
8. An immunogenic composition comprising the recombinant rotavirus of claim 1 .
9. The immunogenic composition of claim 8 , wherein the immunogenic composition is formulated for oral, subcutaneous, or intramuscular administration.
10. A recombinant rotavirus expression system comprising:
a nonstructural protein 3 (NSP3) expression vector including a nucleotide sequence encoding an intact, full-length rotavirus (NSP3) and a nucleotide sequence encoding a non-rotavirus polypeptide, wherein the NSP3 and the non-rotavirus polypeptide are encoded by a single open reading frame, separated by a self-cleavage protease domain;
a VP1 expression vector;
VP2 expression vector;
a VP3 expression vector;
a VP4 expression vector;
a VP6 expression vector;
a VP7 expression vector;
a NSP1 expression vector;
a NSP2 expression vector;
a NSP4 expression vector;
a NSP5/6 expression vector; and
an African Swine Fever Virus NP868R RNA capping enzyme expression vector.
11. The recombinant rotavirus expression system of claim 10 ,
wherein each of the NSP3 expression vector, VP1 expression vector, VP2 expression vector, VP3 expression vector, VP4 expression vector, VP6 expression vector, VP7 expression vector, NSP1 expression vector, NSP2 expression vector, NSP4 expression vector, and NSP5/6 expression vector are T7 expression vectors.
12. The recombinant rotavirus expression system of claim 10 , wherein the self-cleavage protease domain is a 2A cleavage element.
13. The recombinant rotavirus expression system of claim 10 , wherein the non-rotavirus polypeptide is derived from a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus.
14. The recombinant rotavirus expression system of claim 10 , wherein the non-rotavirus polypeptide induces an immunological response against a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus.
15. The recombinant rotavirus expression system of claim 10 , wherein the non-rotavirus polypeptide is selected from the group consisting of norovirus VP1 protein, norovirus P domain, and norovirus P2 domain.
16. The recombinant rotavirus expression system of claim 10 ,
wherein the rotavirus reverse genetics system is based upon serotype G1P [8].
17. A method for producing a recombinant rotavirus, the method comprising:
transfecting BHK-T7 cells with the recombinant rotavirus expression system of claim 10 ;
overseeding the transfected BHK-T7 cells with MA104 cells;
preparing a clarified cell lysate; and
isolating recombinant rotavirus.